ABSTRACT:In Leishmania the glutathione/glutathione reductase eukaryotic redox system is replaced by the unique trypanothione/trypanothione reductase (TR) system. In vitro, silver is a more effective TR inhibitor than antimony, the first line drug against leishmaniasis in most endemic countries, and its mechanism of inhibition is similar to that of Sb(III). In particular, silver binds with high affinity to the catalytic triad Cys52, Cys57, and His461 0 , thereby inhibiting TR. Here, Ag(0) activity was tested on the promastigote and amastigote stages of Leishmania infantum using a drug-delivery system consisting in Ag(0) nanoparticles encapsulated by ferritin molecules (PfFt-AgNPs). These were able to induce an antiproliferative effect on the parasites at metal concentrations lower than those used with antimony.KEYWORDS: Trypanothione reductase, Leishmania, silver, nanoparticles, drug delivery L eishmaniasis affects at present 12 million people worldwide. 1Because effective vaccines are not yet available, the chemotherapy remains the only treatment option for controlling the infection. Except for the recent encouraging advances in chemotherapy obtained with amphotericin B and its new liposomal formulations, miltefosine and paromomycin, the treatment modalities for leishmaniasis infections mostly rely on antimony-based drugs, which date back over 60 years and suffer from poor efficacy, high toxicity, and increasing resistance. 2 The Leishmania life cycle involves two principal morphological stages, promastigote and amastigote. The first one develops within an insect vector, a phlebotomine sand-fly; the second one infects the macrophages of vertebrate hosts, which produce considerable amounts of H 2 O 2 to eliminate intruding parasites. The search for urgently needed drugs against Leishmania parasites is focusing on metabolic pathways vital for the amastigote parasite and distinct from the analogous metabolism in the mammalian host. In this respect, the trypanothione metabolism enzymes are considered as promising targets of new drugs against leishmaniasis.The trypanothione (T(SH) 2 ) is synthesized from glutathione and spermidine by the trypanothione synthetase (TryS) and is kept reduced by the trypanothione reductase (TR). Trypanothione participates in crucial thiol-disulfide exchange reactions and serves as electron donor in several metabolic pathways, from synthesis of DNA precursors to oxidant detoxification. The T(SH) 2 /TR system replaces many of the antioxidant and metabolic functions of the glutathione/glutathione reductase (GR) and thioredoxin/thioredoxin reductase (TrxR) systems present in other organisms and therefore is necessary for the parasite survival. 3-5 Sb(V), reduced inside the amastigote to Sb(III), 6 interferes in vivo with the T(SH) 2 metabolism by inducing rapid efflux of intracellular T(SH) 2 and inhibiting TR in intact cells. 7